✎ Contributed by Ty Griffin
Co-Diagnostics (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal and Sri Lanka, significantly increasing its addressable market to an estimated $13.0 billion. The expansion supports planned commercialization of the CoSara PCR Pro(R) point-of-care platform and SARAGENE(R) product line, subject to regulatory approvals, as the company builds regional distribution channels and positions for broader deployment of its molecular diagnostics solutions.
To view the full press release, visit https://ibn.fm/2aATV
About Co-Diagnostics, Inc.
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
For more information, https://co-dx.com/
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]